Travere Therapeutics TVTX shares surged 37.2% on Tuesday after the company announced that the FDA approved Filspari ...

Expanded indication supported by mixed bag of trial data ...

Proteinuria is a condition characterised by the presence of excess protein, mainly albumin, in the urine. Generally, the kidneys filter waste products and excess fluids from the blood and excrete them ...

Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...

Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...

On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis, a rare kidney disorder. ・The company estimates that over 30,000 people in the U.S.

Please provide your email address to receive an email when new articles are posted on . Remission of proteinuria to less than 0.3 g per day was linked to greater eGFR preservation for patients with ...

Proteinuria is common in the adult population and its clinical significance can vary widely. A clear diagnostic process is needed to identify the cause of the findings and guide the treatment ...